Autoreactive B cell responses targeting nuclear antigens in systemic sclerosis: Implications for disease pathogenesis

Area of Science:

• Immunology
• Rheumatology
• Autoimmunity

Background:

• Systemic sclerosis (SSc) is characterized by autoreactive B cell responses targeting nuclear proteins.
• Antinuclear autoantibodies (ANAs), including anti-topoisomerase 1 (ATA), anti-centromere protein (ACA), anti-RNA polymerase III (ARA), and anti-fibrillarin (AFA), are common and specific biomarkers in SSc.
• These autoantibodies aid in diagnosing SSc and identifying clinical phenotypes.

Purpose of the Study:

• To investigate the contribution of antinuclear autoantibodies and underlying B cell responses to SSc pathogenesis.
• To address the poor understanding of factors driving SSc progression and individual patient trajectories.
• To inform the development of more effective, targeted therapies for SSc.

Main Methods:

• Review of existing literature on SSc pathogenesis and autoantibody profiles.
• Analysis of clinical data correlating autoantibody presence with disease phenotypes and progression.
• Evaluation of evidence supporting B cell targeting therapies in SSc.

Main Results:

• Autoreactive B cells and specific ANAs are central to SSc pathogenesis.
• Current understanding of disease progression drivers and predictive factors remains limited.
• Patient heterogeneity contributes to variable treatment responses in clinical trials.

Conclusions:

• Antinuclear autoantibodies are key diagnostic and phenotypic markers in SSc.
• Further research into B cell responses is essential for understanding SSc progression.
• Targeting B cells may offer therapeutic benefits for select SSc patients.